// App-Quantinova.ai

169 : Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through three years: long-term data from the FUTURE 1 and FUTURE 2 studies

Researchers

Presenter

  • Hector Chinoy

Principal Investigators

  • Laure Gossec

  • Tore K Kvien

  • Philip G Conaghan

  • Mikkel stergaard

  • Dafna Gladman

  • Philip Mease

  • Lawrence Rasouliyan

  • Luminita Pricop

  • Corine Gaillez

  • Steffen Jugl

Medical Centers

  • Division of Musculoskeletal and Dermatological Sciences, University of Manchester, Manchester, United Kingdom

  • Rheumatology, UPMC University Paris 06 and Pitie-Salpétriere Hospital, Paris, FRANCE

  • Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

  • NIHR Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UNITED KINGDOM

  • Copenhagen Center for Arthritis Research (COPECARE), Rigshospitalet, Glostrup, DENMARK

  • Toronto General Hospital, University of Toronto, Toronto, ON, Canada

  • Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

  • Biostatistics, RTI Health Solutions, Barcelona, Spain,

  • Oncology Clinical Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ

  • Immunology & Dermatology Franchise, Novartis Pharma AG, Basel, SWITZERLAND

Locations

  • United Kingdom

  • France

  • Norway

  • Denmark

  • Canada

  • United States

  • Spain

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved